Zhejiang Lepu Pharmaceutical Co.,Ltd. (formerly known as Zhejiang Neo-Dankong Pharmaceutical Co.,Ltd.), founded in 2001, with an area of 152,000 square meters, is now located in Jiaojiang Chemical API Industrial Park, Taizhou City, Zhejiang Province. In 2014, Lepu Medical Technology (Beijing) Co., Ltd. was introduced into the management then becoming the controlling shareholder. In 2018, the name of "Zhejiang Lepu" was officially announced.
Zhejiang Lepu is mainly engaged into R&D, production and sales of APIs and FDFs for Cardiovascular, Antibiotics, Oncology, Nervous System and other categories. Main products include Atorvastatin Calcium, Norfloxacin, Rosuvastatin Calcium, etc. A solid GMP system has been well established, with certifications including CFDA for China, FDA for USA, MHRA for UK, COS for EU, PMDA for Japan, KFDA for South Korea, etc. Many product categories are taking the global-leading positions.
The company has state-level academician workstation and joint laboratories with renowned universities and research institutes, including Tsinghua University, Nankai University, Zhejiang University of Technology, China State Institute of Pharmaceutical Industry, now recognized as a state-level high-tech enterprise. We have extensive cooperation with more than 20 international pharmaceutical companies, speeding up the R&D of cardiovascular, oncology and other new drugs which provides sustainable power for medium and long-term development for the company.
In the future, Zhejiang Lepu will be adhering to the core values of "Honesty, Innovation, Integrity, Synergy"and the enterprise spirit of "Dedication, Law-abiding, Contribution", working diligently to be explorative and innovative. We will continue to enhance our core strength through innovation, to excel in the production of APIs and FDFs, striving to become a modern pharmaceutical enterprise with international competitiveness.